Cara Therapeutics Inc. [CARA] Stock sold by Insider Posner Christopher for $13222.0


Cara Therapeutics Inc.’s filing revealed that its President and CEO Posner Christopher unloaded Company’s shares for reported $13222.0 on Aug 03. In the deal valued at $3.07 per share,4,307 shares were sold. As a result of this transaction, Posner Christopher now holds 168,207 shares worth roughly $ 0.36 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, Menzaghi Frederique Ph.D. sold 2,993 shares, generating $10,505 in total proceeds. Upon selling the shares at $3.51, the Chief Scientific Off,SVP-R&D now owns 153,747 shares.

Before that, Goncalves Joana sold 2,723 shares. Cara Therapeutics Inc. shares valued at $9,558 were divested by the Chief Medical Officer at a price of $3.51 per share. As a result of the transaction, Goncalves Joana now holds 53,681 shares, worth roughly $0.12 million.

BofA Securities downgraded its Cara Therapeutics Inc. [CARA] rating to an Underperform from a a Neutral in a research note published on Tuesday, March 08, 2023; the price target was decreased to $6 from $13. PT values the company’s stock at a premium of 64.0 to its Tuesday closing price.

Price Performance Review of CARA

On Tuesday, Cara Therapeutics Inc. [NASDAQ:CARA] saw its stock fall -10.00% to $2.16. On the same session, the stock had its day’s lowest price of $2.11, but rose to a high of $2.46. Over the last five days, the stock has lost -23.13%. Cara Therapeutics Inc. shares have fallen nearly -79.89% since the year began. Nevertheless, the stocks have fallen -80.13% over the past one year. While a 52-week high of $12.81 was reached on 02/03/23, a 52-week low of $2.36 was recorded on 09/05/23. SMA at 50 days reached $2.92, while 200 days put it at $6.48. A total of 1.49 million shares were traded, compared to the trading of 1.56 million shares in the previous session.

Levels Of Support And Resistance For CARA Stock

The 24-hour chart illustrates a support level at 2.03, which if violated will result in even more drops to 1.89. On the upside, there is a resistance level at 2.38. A further resistance level may holdings at 2.59. The Relative Strength Index (RSI) on the 14-day chart is 22.46, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.41, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.74%. Stochastics %K at 5.56% indicates the stock is a buying.

How much short interest is there in Cara Therapeutics Inc.?

A steep rise in short interest was recorded in Cara Therapeutics Inc. stocks on Aug 14, 2023, dropping by -1.35 million shares to a total of 2.62 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 3.97 million shares. There was a decline of -51.53%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 6.80% of the overall stock float, the days-to-cover ratio (short ratio) fell to 3.8.

Cara Therapeutics Inc. [CARA] – Who Are The Largest Shareholders?

In filings from BlackRock Fund Advisors, it is revealed that the company now owns 3,346,116 shares, or roughly 6.20% of the outstanding CARA shares. In other words, the investor’s shares have fallen by -3,751,484 from its previous 13-F filing of 7097600.0. Additionally, The Vanguard Group, Inc. decreased -16.36% of its stake after which the total value it holdings stand at $8,503,884, while Disciplined Growth Investors, Inc added 1.84% of its stake to hold $5.87 million in the firm. Over the last quarter, Farallon Capital Management LLC sold -328,779 shares of Cara Therapeutics Inc., while Chescapmanager LLC sold 495,184 shares. At present, Jacobs Levy Equity Management, In is holding 1,022,882 shares valued at $3.41 million. ClearBridge Investments LLC owned 998,074 shares of the company at the time of its most recent 13F filing, worth $3.32 million.


Please enter your comment!
Please enter your name here